Evaluation and Management of Hepatocellular Carcinoma

Clinics in Liver Disease

Volumn 19, Issue 1, 2015, Pages 23-43

  Kulik, Laura M ^a   Chokechanachaisakul, Attasit ^a  

^a Kovler Organ Transplantation Center NMH Arkes Family Pavilion   (United States)

Author keywords

Diagnosis; Evaluation; Hepatocellular carcinoma; Management; Treatment

Indexed keywords

DRUG ELUTING BEAD; EVEROLIMUS; NANOBEAD; PRAVASTATIN; SORAFENIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; YTTRIUM 90; ANTINEOPLASTIC AGENT;

ABLATION THERAPY; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RISK; CANCER SURGERY; CANCER THERAPY; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SURVEILLANCE; HUMAN; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER RESECTION; LOCOREGIONAL THERAPY; META ANALYSIS (TOPIC); ORTHOTOPIC TRANSPLANTATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SUSCEPTIBILITY WEIGHTED IMAGING; SYSTEMIC THERAPY; TRANSARTERIAL CHEMOEMBOLIZATION; TRANSARTERIAL RADIOEMBOLIZATION; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; COMPLICATION; HEALTH SURVEY; HEPATITIS B; LIVER NEOPLASMS; LIVER TRANSPLANTATION; VIROLOGY;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; POPULATION SURVEILLANCE;

EID: 84927631956     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2014.09.002     Document Type: Review

References (134)

1. Altekruse S.F., McGlynn K.A., Reichman M.E. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. JClin Oncol 2009, 27:1485-1491.
2. El-Serag H., Kanwal F. Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go?. Hepatology 2014, [Epub ahead of print].
3. Altekruse S.F., McGlynn K.A., Dickie L.A., et al. Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992-2008. Hepatology 2012, 55:476-482.
4. Llovet J.M., Brú C., Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999, 19(3):329-338.
5. Yau T., Tang V.Y., Yao T.J., et al. Development of Hong Kong liver cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology 2014, 146:1697-1700.
6. Mazzaferro V., Majno P. Principles for the best multidisciplinary meetings. Lancet Oncol 2011, 12(4):323-325.
7. Zhang J., Yang B.H., Tang Z.Y., et al. Randomized controlled trial of screening for hepatocellular carcinoma. JCancer Res Clin Oncol 2004, 130(7):417-422.
8. Poustchi H., Farrell G.C., Strasser S.I., et al. Feasability of conducting a randomized controlled trial for liver cancer screening: is a randomized controlled trial for liver cancer screening feasible or still needed?. Hepatology 2011, 54(6):1998-2004.
9. Singal A.G., Pillai A., Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med 2014, 11(4):e1001624.
10. Sheu J.C., Sung J.L., Chen D.S., et al. Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology 1985, 89:259-266.
11. Barbara L., Benzi G., Gaiani S., et al. Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology 1992, 16:132-137.
12. Okazaki N., Yoshino M., Yoshida T., et al. Evaluation of the prognosis for small hepatocellular carcinoma based on tumor volume doubling time. A preliminary report. Cancer 1989, 63:2207-2210.
13. Santi V., Trevisani F., Gramenzi A., et al. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. JHepatol 2010, 53:291-297.
14. Trinchet J., Chaffaut C., Bourcier V., et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology 2011, 54:1987-1997.
15. Bruix J., Sherman M. Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236.
16. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. JHepatol 2012, 56(4):908-943.
17. Andersson K.L., Salomon J.A., Goldie S.J., et al. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2008, 6:1418-1424.
18. Sato T., Tateshi R., Yoshida H., et al. Ultrasound surveillance for early detection of hepatocellular carcinoma among patients with chronic hepatitis C. Hepatol Int 2009, 3:544-550.
19. Thompson Coon J., Rogers G., Hewson P., et al. Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis. Br J Cancer 2008, 98:1166-1175.
20. Del Poggio P., Olmi S., Ciccarese F., et al. Factors that affect efficacy of ultrasound surveillance for early stage hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2014, [Epub ahead of print].
21. Forner A., Reig M., Bruix J. Alpha-fetoprotein for hepatocellular carcinoma diagnosis: the demise of a brilliant star. Gastroenterology 2009, 137:26-29.
22. Di Bisceglie A.M., Sterling R.K., Chung R.T., et al. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. JHepatol 2005, 43(3):434-441.
23. Marrero J., Feng Z., Wang Y., et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009, 137:110-118.
24. Singal A.G., Yopp A., S Skinner C., et al. Utilization of hepatocellular carcinoma surveillance among American patients: a systematic review. JGen Intern Med 2012, 27(7):861-867.
25. Davila J.A., Morgan R.O., Richardson P.A., et al. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology 2010, 52:132-141.
26. Dalton-Fitzgerald E., Tiro J., Kandunoori P., et al. Practice patterns and attitudes of primary care providers and barriers to surveillance of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2014, [Epub ahead of print].
27. Forner A., Vilana R., Ayuso C., et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008, 47:97-104.
28. de Lope C.R., Tremosini S., Forner A., et al. Management of HCC. JHepatol 2012, 56(Suppl 1):S75-S87.
29. Jarnagin W.R., Gonen M., Fong Y., et al. Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg 2002, 236(4):397-406.
30. Poon R., Fan S.T., Lo C.M., et al. Improving perioperative outcome expands the role of hepatectomy in management of benign and malignant hepatobiliary diseases: analysis of 1222 consecutive patients from a prospective database. Ann Surg 2004, 240:698-710.
31. Lui C.L., Fan S.T., Lo C.M., et al. Abdominal drainage after hepatic resection is contraindicated in patients with chronic liver diseases. Ann Surg 2004, 239:194-201.
32. Dimick J.B., Cowan J.A., Knol J.A., et al. Hepatic resection in the United States: indications, outcomes, and hospital procedural volumes from a nationally representative database. Arch Surg 2003, 138:185-191.
33. Llovet J.M., Schwartz M., Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005, 25(2):181-200.
34. Llovet J.M., Fuster J., Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999, 30:1434-1440.
35. Vauthey J.N., Pawlik T.M., Lauwers G.Y., et al. Is hepatic resection for large or multi-nodular hepatocellular carcinoma justified? Results from a multi-institutional database. Ann Surg Oncol 2005, 12(5):364-373.
36. Yang L.Y., Fang F., Ou D.P., et al. Solitary large hepatocellular carcinoma: a specific subtype of hepatocellular carcinoma with good outcome after hepatic resection. Ann Surg 2009, 249(1):118-123.
37. Shah S.A., Wei A.C., Cleary S.P., et al. Prognosis and results after resection of very large (>10 cm) hepatocellular carcinoma. JGastrointest Surg 2007, 11:589-595.
38. Cucchetti A., Ercolani G., Vivarelli M., et al. Impact of model for end-stage liver disease (MELD) score on prognosis after hepatectomy for hepatocellular carcinoma on cirrhosis. Liver Transpl 2006, 12:966-971.
39. Teh S.H., Sheppard B.C., Schwartz J., et al. Model for end-stage liver disease score fails to predict perioperative outcome after hepatic resection for hepatocellular carcinoma in patients without cirrhosis. Am J Surg 2008, 195:697-701.
40. Makuuchi M., Kosuge T., Takayama T., et al. Surgery for small liver cancers. Semin Surg Oncol 1993, 9:298-304.
41. Truty M.J., Vauthey J.N. Surgical resection of high-risk hepatocellular carcinoma: patient selection, preoperative considerations and operative technique. Ann Surg Oncol 2010, 17:1219-1225.
42. Kubota K., Makuuchi M., Kusaka K., et al. Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors. Hepatology 1997, 26(5):1176-1181.
43. Ribero D., Abdalla E., Madoff D., et al. Portal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome. Br J Surg 2007, 94(11):1386-1394.
44. Farges O., Belghiti J., Kianmanesh R., et al. Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg 2002, 237:208-217.
45. Palavencino M., Chun Y.S., Madoff D.C., et al. Major hepatic resection for hepatocellular carcinoma with or without portal vein embolization: perioperative outcome and survival. Surgery 2009, 145:399-405.
46. Ishizawa T., Hasegawa K., Aoki T., et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 2008, 134(7):1908-1916.
47. Pawlik T.M., Poon R.T., Abdalla E.K., et al. Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study. Surgery 2005, 137(4):403-410.
48. Imamura H., Matsuyama Y., Tanaka E., et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. JHepatol 2003, 38:200-207.
49. Ikai I., Arii S., Kojiro M., et al. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer 2004, 101:796-802.
50. Shi M., Guo R.P., Lin X.J., et al. Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial. Ann Surg 2007, 245:36-43.
51. Katz S.C., Shia J., Liau K.H., et al. Operative blood loss independently predicts recurrence and survival after resection of hepatocellular carcinoma. Ann Surg 2009, 249:617-623.
52. Ye J.Z., Miao Z.G., Wu F.X., et al. Recurrence after anatomic resection versus nonanatomic resection for hepatocellular carcinoma: a meta analysis. Asian Pac J Cancer Prev 2012, 13:1771-1777.
53. NCCN guidelines version 2.2014. Panel members hepatobiliary cancers.
54. Bruix J., Takayama T., Mazzaferro V., et al. STORM: a phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrent of hepatocellular carcinoma (HCC). JClin Oncol 2014, 32:5s. suppl; abstr 4006.
55. Shindoh J., Hasegawa K., Matsuyama Y., et al. Low hepatitis C viral load predicts better long-term outcomes in patients undergoing resection of hepatocellular carcinoma irrespective of serologic eradication of hepatitis C virus. JClin Oncol 2013, 31(6):766-773.
56. Iwatsuki S., Gordon R.D., Shaw B.W., et al. Role of liver transplantation in cancer therapy. Ann Surg 1985, 202(4):401.
57. Mazzaferro V., Regalia E., Doci R., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. NEngl J Med 1996, 334:693-699.
58. Mazzaferro V., Bhoori S., Sposito C., et al. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence based analysis of 15 years of experience. Liver Transpl 2011, 17:S44-S57.
59. Policy 9: allocation of liver and liver-intestines. Organ Procurement and Transplant Network (OPTN) policies. Available at: . Accessed July 01, 2014. http://www.unos.org/.
60. Volk M.L., Vijan S., Marrero J.A. Anovel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria. Am J Transplant 2008, 8(4):839-846.
61. Clavien P., Lesurtel M., Bossuyt P.M., et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012, 13:e11-e22.
62. Yao F.Y., Bass N.M., Nikolai B., et al. Liver transplantation for hepatocellular carcinoma: analysis of survival according to intention-to-treat principle and dropout from the waiting list. Liver Transpl 2002, 8:873-883.
63. Yao F.Y., Bass N.M., Nikolai B., et al. Afollow up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy. Liver Transpl 2003, 9:684-692.
64. Toso C., Mentha G., Kneteman N.M., et al. The place of downstaging for hepatocellular carcinoma. JHepatol 2010, 52:930-936.
65. Yao F., Kerlan R.K., Hirose R., et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 2008, 48:819-827.
66. Yao FY, Mehta N, Fix OK, etal. Down-staging of hepatocellular carcinoma to within Milan criteria prior to liver transplantation: comparison of long-term outcome with tumors meeting Milan criteria without requiring down-staging. AASLD. Boston, November 9-13, 2012.
67. Mehta N, Yao FY, Roberts JP, etal. Intention-to-treat outcome of T1 hepatocellular carcinoma. Using the approach of "wait and not ablate" until meeting T2 criteria for liver transplant listing. Presented at AASLD. WashingtonDC, November 01-05, 2013.
68. SRTR & OPTN annual data report, 2011.
69. Abecassis M.M., Fisher R.A., Olthoff K.M., et al. Complications of living donor hepatic lobectomy-a comprehensive report. Am J Transplant 2012, 12(5):1208-1217.
70. Kulik L., Abecassis M. Living donor liver transplantation for hepatocellular carcinoma. Gastroenterology 2004, 127(5 Suppl 1):S277-S282.
71. Bhangui P., Vibert E., Majno P., et al. Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma: living versus decreased donor transplantation. Hepatology 2011, 53(5):1570-1579.
72. Kulik L.M., Fisher R.A., Rodrigo D.R., et al. Outcomes of living and deceased donor liver transplant recipients with hepatocellular carcinoma: results of the A2ALL cohort. Am J Transplant 2012, 12(11):2997-3007.
73. Belghiti J., Cortes A., Abdalla E.K., et al. Resection prior to liver transplantation for hepatocellular carcinoma. Ann Surg 2003, 238(6):885-892.
74. Hwang S., Lee S.G., Moon D.B., et al. Salvage living donor liver transplantation after prior liver resection for hepatocellular carcinoma. Liver Transpl 2007, 13(5):741-746.
75. Del Gaudio M., Ercolani G., Ravaioli M., et al. Liver transplantation for recurrent hepatocellular carcinoma on cirrhosis after liver resection: University of Bologna experience. Am J Transplant 2008, 8(6):1177-1185.
76. Cucchetti A., Vitale A., Del Gaudio M., et al. Harm and benefits of primary liver resection and salvage transplantation for hepatocellular carcinoma. Am J Transplant 2010, 10:619-627.
77. Fuks D., Dokmak S., Paradis V., et al. Benefit of initial resection of hepatocellular carcinoma followed by transplantation in case of recurrence: an intention-to-treat analysis. Hepatology 2012, 55:132-140.
78. Sala M., Forner A., Varela M., et al. Prognostic prediction in patients with hepatocellular carcinoma. Semin Liver Dis 2005, 25:171-180.
79. Schwartz M., Roayaie S., Llovet J. How should patients with hepatocellular carcinoma recurrence after liver transplantation be treated?. JHepatol 2005, 43(4):584-589.
80. Roberts J.P., Venook A., Kerlan R., et al. Hepatocellular carcinoma: ablate and wait versus rapid transplantation. Liver Transpl 2010, 16(8):925-929.
81. Otto G., Herber S., Heise M., et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 2006, 12(8):1260-1267.
82. Vitale A., D'Amico F., Frigo A.C., et al. Response to therapy as a criterion for awarding priority to patients with hepatocellular carcinoma awaiting liver transplantation. Ann Surg Oncol 2010, 17(9):2290-2302.
83. Mailey B., Artinyan A., Khalili J., et al. Evaluation of absolute serum alpha-fetoprotein levels in liver transplant for hepatocellular cancer. Arch Surg 2011, 146(1):26-33.
84. Berry K., Ioannou G.N. Serum alpha-fetoprotein level independently predicts post transplant survival in patients with hepatocellular carcinoma. Liver Transpl 2013, 19(6):634-645.
85. Merani S., Majno P., Kneteman N.M., et al. The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. JHepatol 2011, 55(4):814-819.
86. Pomfret E.A., Washburn K., Wald C., et al. Report of a national conference of liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl 2010, 16:262-278.
87. Orlando A., Leandro G., Olivo M., et al. Radiofrequency thermal ablation vs.percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. Am J Gastroenterol 2009, 104(2):514-524.
88. Cho Y.K., Kim J.K., Kim M.Y., et al. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 2009, 49(2):453-459.
89. Livraghi T., Meloni F., Di Stasi M., et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice?. Hepatology 2008, 47(1):82-89.
90. Huang S., Yu J., Liang P., et al. Percutaneous microwave ablation for hepatocellular carcinoma adjacent to large vessels: a long term follow up. Eur J Radiol 2014, 83:552-558.
91. Ni J.Y., Shan S., Xu L.F., et al. Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol 2013, 19(24):3872-3882.
92. Huang J., Yan L., Cheng Z., et al. Arandomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg 2010, 252(6):903-912.
93. Molinari M., Helton S. Hepatic resection versus radiofrequency ablation for hepatocellular carcinoma in cirrhotic individuals not candidates for liver transplantation: a Markov model decision analysis. Am J Surg 2009, 198(3):396-406.
94. Llovet J.M., Real M.I., Montaña X., et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002, 359(9319):1734-1739.
95. Lo C.M., Ngan H., Tso W.K., et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002, 35(5):1164-1171.
96. Georgiades C.S., Hong K., D'Angelo M., et al. Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. JVasc Interv Radiol 2005, 16(12):1653-1659.
97. Varela M., Real M.I., Burrel M., et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. JHepatol 2007, 46(3):474-481.
98. Lencioni R., De Baere T., Burrel M., et al. Transcatheter treatment of hepatocellular carcinoma with doxorubicin DC beads (DEBDOX): technical recommendations. Cardiovasc Intervent Radiol 2012, 35(5):980-985.
99. Pawlik T.M., Reyes D., Cosgrove D., et al. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. JClin Oncol 2011, 29(30):3960-3967.
100. Kalva S., Pectasides M., Liu R., et al. Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma. Cardiovasc Intervent Radiol 2014, 37(2):381-387.
101. Lammer J., Malagari K., Vogl T., et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010, 33(1):41-52.
102. Burrel M., Reig M., Forner A., et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using drug eluting beads. Implications for clinical practice and trial design. JHepatol 2012, 56(6):1330-1335.
103. Nicolini A., Martinetti L., Crespi S., et al. Transarterial chemoembolization with epirubicin-eluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma. JVasc Interv Radiol 2010, 21(3):327-332.
104. Nicolini D., Svegliati-Baroni G., Candelari R., et al. Doxorubicin-eluting bead vs conventional transcatheter arterial chemoembolization for hepatocellular carcinoma before liver transplantation. World J Gastroenterol 2013, 19(34):5622-5632.
105. Salem R., Thurston K.G. Radioembolization with 90Yttrium microspheres: a state of the art brachytherapy treatment for primary and secondary malignancies: part 1: technical and methodologic considerations. JVasc Interv Radiol 2006, 17:1251-1278.
106. Salem R., Lewandowski R.J., Mulcahy M.F., et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010, 138(1):52-64.
107. Hilgard P., Hamami M., Fouly A.E., et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology 2010, 52(5):1741-1749.
108. Sangro B., Carpanese L., Cianni R., et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona Clinic Liver Cancer stages: a European evaluation. Hepatology 2011, 54:868-878.
109. Mazzaferro V., Sposito C., Bhoori S., et al. Yttrium-90 radioembolization for intermediate- advanced hepatocellular carcinoma: a phase 2 study. Hepatology 2013, 57:1826-1837.
110. Golfieri R., Renzulli M., Mosconi C., et al. Hepatocellular carcinoma responding to superselective transarterial chemoembolization: an issue of nodule dimension?. JVasc Interv Radiol 2013, 24(4):509-517.
111. Lewandowski R.J., Kulik L.M., Riaz A., et al. Acomparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 2009, 9(8):1920-1928.
112. Vouche M., Lewandowski R.J., Atassi R., et al. Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. JHepatol 2013, 59(5):1029-1036.
113. Salem R., Lewandowski R.J., Kulik L., et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011, 140(2):497-507.e2.
114. Moreno-Luna L.E., Yang J.D., Sanchez W., et al. Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma. Cardiovasc Intervent Radiol 2013, 36(3):714-723.
115. Salem R., Gilbertsen M., Butt Z., et al. Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroenterol Hepatol 2013, 11(10):1358-1365.
116. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. NEngl J Med 2008, 359(4):378-390.
117. Cheng A.L., Kang Y.K., Chen Z., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009, 10(1):25-34.
118. Lencioni R, Venook A, Marrero J, etal. Second interim results of the GIDEON (Global Investigation of Therapeutic Decisions in HCC and of its Treatment with Sorafenib) study: Barcelona-Clinic Liver Cancer (BCLC) Stage Subgroup Analysis. In European Multidisciplinary Cancer Congress (ECCO-ESMO). Stockholm, Sweden, September 23-27, 2011.
119. Pinter M., Sieghart W., Hucke F., et al. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. Aliment Pharmacol Ther 2011, 34(8):949-959.
120. Cheng A., Kang D., Lin J., et al. Phase III trial of sunitib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC). JClin Oncol 2011, 29. supp;abstract4000.
121. Johnson P, Qin S, Park JW, etal. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the phase 3 BRISK-FL study. Presented at AASLD. Boston, September 11-13, 2012; Abstract LB-6.
122. Llovet JM, Decaens T, Raoul J, etal. Brivanib versus placebo in patients with advanced hepatocellular carcinoma (HCC) who failed or were intolerant to sorafenib: results from the BRISK-PS trial. EASL. Barcelona, Spain, April 18-22, 2012; Abstract 1398.
123. Cainap C., Qin S., Huang W.T., et al. Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC). JClin Oncol 2013, 31(Suppl 4):249.
124. Santoro A., Rimassa L., Borbath I., et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol 2013, 14(1):55-63.
125. Truesdale A.E., Caldwell S.H., Shah N.L., et al. Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant. Transpl Int 2011, 24(10):991-998.
126. Frenette C.T., Boktour M., Burroughs S.G., et al. Pre-transplant utilization of sorafenib is not associated with increased complications after liver transplantation. Transpl Int 2013, 26(7):734-739.
127. Vouche M., Kulik L., Atassi R., et al. Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: imaging analysis from a prospective randomized trial of Y90+/- sorafenib. Hepatology 2013, 58(5):1655-1666.
128. Kulik L., Vouche M., Koppe S., et al. Prospective randomized pilot study of Y90+/-sorafenib as bridge to transplantation in hepatocellular carcinoma. JHepatol 2014, 61(2):309-317.
129. Kudo M., Imanaka K., Chida N., et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 2011, 47(14):2117-2127.
130. Sansonno D., Lauletta G., Russi S., et al. Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. Oncologist 2012, 17(3):359-366.
131. Lencioni R., Llovet J.M., Han G., et al. Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): phase II, randomized, double-blind SPACE trial. JClin Oncol 2012, 30(Suppl 4). [abstract: LBA154].
132. Zhang L., Hu P., Chen X., Bie P. Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis. PLoS One 2014, 9(6):e100305.
133. Bravi F., Bosetti C., Tavani A., et al. Coffee reduces risk for hepatocellular carcinoma: an updated meta-analysis. Clin Gastroenterol Hepatol 2013, 11(11):1413-1421.
134. Finkelmeier F., Kronenberger B., Köberle V., et al. Severe 25-hydroxyvitamin D deficiency identifies a poor prognosis in patients with hepatocellular carcinoma-a prospective cohort study. Aliment Pharmacol Ther 2014, 39(10):1204-1212.